Newsletter 24/2025
/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! Holidays are in the air, but we still have something new for you this week! Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE. […]
Cholesterol Identified as Key Shield in Heat-Resistant Cancer Cells
/in Hyperthermia, Preclinical Research/by MaxATRN-119: A New Promising ATR Inhibitor for ATM Mutations (And Other HRR Mutations)
/in Not PCa related/by MaxUPDATE: OncoACP3 Moving to Phase 1 Trial as Therapeutic Agent
/in Clinical Trial, Metastatic, Phase 1/by MaxSn-117m-DTPA Emerges as Theranostic: Phase 1/2 Trials
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxNewsletter 23/2025
/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! For biology discovery enthusiasts (and AI applications) like me, last week was really exciting! But we also have good news on the clinical trial front! Stay strong and fight on! As usual, we also have a podcast if you […]
Phase 1 Trial of XL309: USP1 Inhibitor Targeting DNA Repair in Solid Tumors
/in Clinical Trial, Metastatic, Phase 1/by MaxUPDATE About ACE-232: Phase 1 Trial of a Novel CYP11A1 Inhibitor for mCRPC
/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Phase 2 Trial: Optimal PSA-Triggered Intermittent Therapy for mHSPC October 15, 2025
- Self-Assembled Nano-PROTAC to Improve Targeted Therapy in Castration-Resistant Prostate Cancer October 15, 2025
- Dual Enzyme Blockade Weakens Prostate Cancer Tumors and Enhances Treatment Effectiveness October 15, 2025
- Phase 3 Trial: Xaluritamig (AMG 509) Plus Abiraterone in mCRPC October 13, 2025